STAT+: Novartis gets multiple sclerosis win with BTK inhibitor

RegulatoryapprovedPositive

AI Analysis

Summary

Novartis has received regulatory approval for a BTK inhibitor in multiple sclerosis treatment. The article also mentions updates on Trump drug pricing deals and GSK's mRNA flu vaccine development acceleration.

Outcome Details

BTK inhibitor approval for multiple sclerosis

Importance:7/10

Sentiment:

0.70

multiple sclerosisBTK inhibitorregulatory approvalNovartis

Related Companies

$NVS

Read the original article

Published by STAT News on September 1, 2026 1:34 PM

Read Original